Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet
Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of single ascending dose of
Y-2 sublingual tablets in healthy male and female adult subjects. The secondary objective is
to characterize the single-dose pharmacokinetics of Y-2 sublingual tablets in healthy male
and female adult subjects.